Abstract
Background Immune checkpoint inhibitor (ICI)-associated arthritis (ICI-AR) significantly affects quality of life and often requires discontinuation of ICI therapy and initiation of immunosuppressive treatment. The aim of this retrospective study was to evaluate the dual efficacy of tocilizumab (TCZ), an anti-IL-6R agent, in the treatment of ICI-AR and the prevention of relapses after ICI rechallenge.
Methods This retrospective single-center study was conducted at our institution from 2020 to the end of 2023. We identified 26 patients who developed ICI-AR. The primary objectives were to evaluate the therapeutic efficacy of TCZ in the treatment of ICI-AR in 26 patients and to evaluate the potential of TCZ as secondary prophylaxis during ICI rechallenge in 11 of them. For the treatment of ICI-AR, patients received prednisone (CS) at a low dose of 0.3 mg/kg tapered at 0.05 mg/kg weekly for six weeks until discontinuation. TCZ was administered at a dose of 8 mg/kg every two weeks. In the subgroup receiving secondary prophylaxis (rechallenge n=11, in 10 patients), TCZ was reintroduced at the same dosage of 8 mg/kg bi-weekly concurrently with ICI rechallenge, and without the addition of CS. A control group of patients (rechallenge n=5, in 3 patients) was rechallenged without TCZ. Secondary endpoints included post rechallenge evaluation of ICI duration, reintroduction of CS > 0.1 mg/kg/day, ICI-RA flares, and disease control rate (DCR). An additional explanatory endpoint was the identification of biomarkers predictive of response to TCZ.
Results The median age of the patients was 70 years. The median follow-up from ICI initiation was 864 days. ICI regimens included anti-PD-(L)1 monotherapy in 17 patients (63%), anti-PD-1 combined with anti-CTLA4 therapy in 8 patients (31%), and anti-PD-1 combined with anti-LAG3 therapy in 1 patient (4%). Among the 20 patients treated with TCZ for ICI-AR, all (100%) achieved an ACR70 response rate, defined as greater than 70% improvement, at 10 weeks. Additionally, 81% of these patients achieved steroid-free remission after 24 weeks on TCZ.
The median follow-up period was 552 days in rechallenged patients. The ICI rechallenge regimens (n=16) included anti-PD-(L)1 monotherapy in thirteen cases (81%) and combination therapy in three cases (19%). The results demonstrated a reduction in ICI-AR relapses upon ICI rechallenge in patients receiving TCZ prophylaxis as compared to patients who did not receive prophylaxis (17% vs 40%). In addition, the requirement for CS at doses exceeding 0.1 mg/kg/day was completely abolished with prophylaxis (0% vs 20%), and the mean duration of ICI treatment was notably extended from 113 days to 206 days. The 12-month post-rechallenge outcomes showed a disease control rate (DCR) of 77%. Importantly, during TCZ prophylaxis, CXCL9 levels remained elevated, showing no decline from their levels at the onset of ICI-AR. Additionally, elevations of IL-6 and CXCL10 levels were exclusively observed in patients who developed new irAEs during the period of TCZ prophylaxis.
Conclusion In addition to its efficacy in treating ICI-AR, TCZ demonstrated efficacy as a secondary prophylactic agent, preventing the recurrence of ICI-AR symptoms and lengthening ICI treatment duration after ICI rechallenge. The use of TCZ as a secondary prophylaxis may represent a promising strategy to extend patient exposure to ICI treatments and maximize therapeutic benefit.
1- TCZ achieved a 100% ACR70 response rate at 24 weeks, demonstrating its efficacy in the treatment of ICI-RA.
2- A significant 81% of patients achieved steroid-free status after 24 weeks on TCZ, underscoring its utility in accelerating CS tapering.
3- TCZ serves as a successful secondary prophylaxis in patients rechallenged with ICI, preventing significant arthritis flares and the need for additional CS use.
4- TCZ prophylaxis reduces the median time to ICI rechallenge by 47.5 days and extends the duration of uninterrupted ICI therapy by 93 days.
5- CXCL9 levels were not reduced during TCZ prophylaxis, suggesting that there was no negative impact on cytokines associated with oncologic response. In addition, early increases in IL-6 and CXCL10 levels may signal the onset of new irAEs during prophylaxis.
Competing Interest Statement
MO received honoraria and speaker fees from Moderna, Roche and BMS.
Funding Statement
This study was funded by CHUV Institutional founding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of canton of Vaud (the Commission Cantonale d'Ethique de la Recherche sur l'Etre Humain (CER-VD)) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
